Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05564039 · ClinicalTrials.gov registry record · Phase 4
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 282
- Enrollment target
NCT05564039 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 282 participants.
The verdict
NCT05564039, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 282 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
Interventions
- DRUG Tirzepatide
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05564039
The ClinicalTrials.gov registry entry for NCT05564039 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT05564039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05564039 about?
NCT05564039 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)". The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
What is the current status of trial NCT05564039?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 282 participants. The study started on 2022-11-30. Estimated completion is 2024-08-12.
What interventions are being tested in trial NCT05564039?
The interventions under investigation include: Tirzepatide (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT05564039?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.